Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

volasertib (NBL-001)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim, Notable Labs, Oncoheroes

Drug class:

PLK1 inhibitor

Related drugs:

‹

›

CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	NBL-001 Sensitive: C3 – Early Trials NBL-001 Sensitive : C3	NBL-001 Sensitive: C3 – Early Trials NBL-001 Sensitive : C3
PIK3CD expression	Mantle Cell Lymphoma	PIK3CD expression	Mantle Cell Lymphoma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	NBL-001 + ERAS-254 Sensitive: D – Preclinical NBL-001 + ERAS-254 Sensitive : D	NBL-001 + ERAS-254 Sensitive: D – Preclinical NBL-001 + ERAS-254 Sensitive : D
PIK3CG expression	Mantle Cell Lymphoma	PIK3CG expression	Mantle Cell Lymphoma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
PIK3CG expression	Mantle Cell Lymphoma	PIK3CG expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CD expression	Mantle Cell Lymphoma	PIK3CD expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CB expression	Mantle Cell Lymphoma	PIK3CB expression	Mantle Cell Lymphoma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
PIK3CB expression	Mantle Cell Lymphoma	PIK3CB expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CA expression	Mantle Cell Lymphoma	PIK3CA expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CA expression	Mantle Cell Lymphoma	PIK3CA expression	Mantle Cell Lymphoma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
CDH1 expression	Non Small Cell Lung Cancer	CDH1 expression	Non Small Cell Lung Cancer	NBL-001 Resistant: D – Preclinical NBL-001 Resistant : D	NBL-001 Resistant: D – Preclinical NBL-001 Resistant : D
CCNA2 expression	Gastric Cancer	CCNA2 expression	Gastric Cancer	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
MCL1 underexpression	T Acute Lymphoblastic Leukemia	MCL1 underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D
MYC underexpression	T Acute Lymphoblastic Leukemia	MYC underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D
BCL2L1 underexpression	T Acute Lymphoblastic Leukemia	BCL2L1 underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	NBL-001 + BI2536 Sensitive: D – Preclinical NBL-001 + BI2536 Sensitive : D	NBL-001 + BI2536 Sensitive: D – Preclinical NBL-001 + BI2536 Sensitive : D
RB1 deletion	Mesothelioma	RB1 deletion	Mesothelioma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D